Knowthestock.com
CRSP - CRISPR Therapeutics AG

Sell

Weak GrowthEarnings/Profit is Negative
WeakStrong
WeakStrong

23%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is -86.13%
Operating Income is Negative
Net Income is Negative
Earnings Per Share (EPS) is Negative
Net Margin is -1023.64%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 15.64
Debt Ratio is 0.16
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.0
Cash Flow
Cash from Operations is Negative
Capital Expenditure not available
Net Increase in Cash is Negative
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
CRISPR Therapeutics AG (CRSP) - www.crisprtx.com
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
Exchange - NASDAQ
Industry - Biological Product (except Diagnostic) Manufacturing
Sector - Manufacturing
CEO - Samarth Kulkarni
Employees - 304
    Close

    Login/Register

    Home


Cookie Policy
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.